Angermann, Christiane E. http://orcid.org/0000-0001-7491-7637
Santos-Gallego, Carlos G.
Requena-Ibanez, Juan Antonio
Sehner, Susanne http://orcid.org/0000-0002-2415-9302
Zeller, Tanja http://orcid.org/0000-0003-3379-2641
Gerhardt, Louisa M. S. http://orcid.org/0000-0003-3052-1563
Maack, Christoph http://orcid.org/0000-0003-3694-4559
Sanz, Javier
Frantz, Stefan
Fuster, Valentin
Ertl, Georg
Badimon, Juan J.
Article History
Received: 15 December 2022
Accepted: 21 September 2023
First Online: 26 October 2023
Competing interests
: C.E.A. reports grant support, personal fees and/or non-financial support from Abbott, AstraZeneca, Boehringer Ingelheim and Eli Lilly, Medtronic, Novo Nordisk, Novartis, ResMed, Thermo Fisher Scientific and Vifor, all outside of the submitted work. C.G.S.-G. reports grant support from Merck, outside of the submitted work. C.M. reports personal fees from Amgen, Abbott, AstraZeneca, Berlin Chemie, Boehringer Ingelheim and Eli Lilly, Bristol-Myers Squibb, Edwards, Novartis, Novo Nordisk, Pharmacosmos and Servier, all outside of the submitted work. T.Z. reports previous funding from Vifor for research-related biobanking, outside of the submitted work. S.F. reports personal fees from Amgen Europe, AstraZeneca, Bayer Vital, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi, Servier and Vifor, all outside of the submitted work. G.E. reports personal fees and/or grant support from Abbott, Bayer, Boehringer Ingelheim and Eli Lilly, Novartis, ResMed and Vifor, all outside of the submitted work. J.J.B. reports grant support by Boehringer Ingelheim and Eli Lilly. All other authors declare no competing interests.